
AveXis Managed Access Program Cohort for Access to AVXS-101
Spinal Muscular AtrophyThe purpose of this Cohort Treatment Protocol will allow access to AVXS-101 for eligible patients diagnosed with SMA.

Expanded Access for CC-2001
DermatologicOtherThis is an expanded access program (EAP) for eligible participants designed to provide access to CC-2001.

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With...
PEComaMalignant3 moreExpanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation

Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
Multiple MyelomaThis is an individual patient, expanded access protocol using Selinexor and dexamethasone ("Sd") for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male, "19023-UMN-01" weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after numerous treatments.

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural...
Multiple SclerosisTo give expanded access to intrathecal autologous MSC-NP treatment to patients with progressive MS who do not meet the inclusion/exclusion criteria of our Phase II stem cell trial.

Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia
Anemia SevereHBOC-201 provides an oxygen treatment bridge and can be used to eliminate, delay, or reduce the need for red blood cell transfusions in anemic patients This is an expanded access IND protocol, and will provide treatment with HBOC-201 to severely anemic adults for whom blood is not an option

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible...
Hurler SyndromeInherited Metabolic Disorder3 moreProviding access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do not meet the eligibility criteria of the BP-U-004 study.

Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
Severe Uncontrolled Atopic DermatitisProvide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease...
STAT1 Gain-of-Function DiseaseExpanded access use of Itacitinib to treat a single patient with aplastic anemia.

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit...
Relapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's LymphomaThis expanded access program will provide continued access to cerdulatinib to eligible participants who experienced clinical benefit from cerdulatinib in Study 13-601 (NCT01994382) and who otherwise meet the eligibility criteria.